These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11954954)

  • 21. Cardiac efficiency improvement after slow continuous ultrafiltration is assessed by beat-to-beat minimally invasive monitoring in congestive heart failure patients: a preliminary report.
    Giglioli C; Landi D; Gensini GF; Valente S; Cecchi E; Scolletta S; Chiostri M; Romano SM
    Blood Purif; 2010; 29(1):44-51. PubMed ID: 19907163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition.
    Chen HH; Lainchbury JG; Harty GJ; Burnett JC
    Circulation; 2002 Feb; 105(8):999-1003. PubMed ID: 11864932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma brain natriuretic peptide predicts short-term clinical outcome in heart failure patients with restrictive filling pattern.
    Feola M; Aspromonte N; Milani L; Bobbio M; Bardellotto S; Barro S; Giovinazzo P; Noventa F; Valle R
    J Card Fail; 2008 Jun; 14(5):420-5. PubMed ID: 18514935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of noninvasive hemodynamic evaluation of the acute effect of levosimendan in advanced heart failure.
    Malfatto G; Della Rosa F; Rella V; Villani A; Branzi G; Blengino S; Giglio A; Facchini M; Parati G
    J Cardiovasc Med (Hagerstown); 2014 Apr; 15(4):322-30. PubMed ID: 24699010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes.
    Chong AY; Freestone B; Patel J; Lim HS; Hughes E; Blann AD; Lip GY
    Am J Cardiol; 2006 Mar; 97(5):671-5. PubMed ID: 16490435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure.
    Yoshimura M; Yasue H; Tanaka H; Kikuta K; Sumida H; Kato H; Jougasaki M; Nakao K
    Br Heart J; 1994 Dec; 72(6):528-33. PubMed ID: 7857734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of human atrial natriuretic peptide on cardiac function and hemodynamics in patients with high plasma BNP levels.
    Nakajima K; Onishi K; Dohi K; Tanabe M; Kurita T; Yamanaka T; Ito M; Isaka N; Nobori T; Nakano T
    Int J Cardiol; 2005 Oct; 104(3):332-7. PubMed ID: 16186065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Skin microvascular distensibility and structural microangiopathy in idiopathic dilated cardiomyopathy and after heart transplantation.
    Sørensen VB; Wroblewski H; Galatius S; Nørgaard T; Haunsø ; Kastrup J
    Microvasc Res; 1999 Jan; 57(1):44-51. PubMed ID: 9882561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma atrial and brain natriuretic peptide levels in dogs with congestive heart failure.
    Asano K; Masuda K; Okumura M; Kadosawa T; Fujinaga T
    J Vet Med Sci; 1999 May; 61(5):523-9. PubMed ID: 10379945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abnormal rhythmic oscillations of atrial natriuretic peptide and brain natriuretic peptide in heart failure.
    Bentzen H; Pedersen RS; Pedersen HB; Nyvad O; Pedersen EB
    Clin Sci (Lond); 2003 Mar; 104(3):303-12. PubMed ID: 12605591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined Assessment of Relaxin and B-Type Natriuretic Peptide Improves Diagnostic Value in Patients With Congestive Heart Failure.
    Han L; Luo J; Bai S; Jia Y; Chen X; Zhao Y; Chen L; Zhu X; Li Y; Jiang Y; Li X; Yang M; Li D; Teng X; Qi Y
    Am J Med Sci; 2017 Nov; 354(5):480-485. PubMed ID: 29173360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low pulse pressure is independently related to elevated natriuretic peptides and increased mortality in advanced chronic heart failure.
    Voors AA; Petrie CJ; Petrie MC; Charlesworth A; Hillege HL; Zijlstra F; McMurray JJ; van Veldhuisen DJ
    Eur Heart J; 2005 Sep; 26(17):1759-64. PubMed ID: 15833758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microvascular distensibility in two different vascular beds in idiopathic dilated cardiomyopathy.
    Wroblewski H; Nørgaard T; Haunsø S; Kastrup J
    Am J Physiol; 1995 Dec; 269(6 Pt 2):H1973-80. PubMed ID: 8594906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nitric oxide synthase activity in peripheral polymorphonuclear leukocytes in patients with chronic congestive heart failure.
    Mitsuke Y; Lee JD; Shimizu H; Uzui H; Iwasaki H; Ueda T
    Am J Cardiol; 2001 Jan; 87(2):183-7. PubMed ID: 11152836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain natriuretic peptide in diagnosis and treatment of heart failure.
    Bhatia V; Nayyar P; Dhindsa S
    J Postgrad Med; 2003; 49(2):182-5. PubMed ID: 12867703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical correlates of elevated plasma natriuretic peptides and Big endothelin-1 in a population of ambulatory patients with heart failure. A substudy of the Italian Network on Congestive Heart Failure (IN-CHF) registry. IN-CHF Investigators.
    Masson S; Gorini M; Salio M; Lucci D; Latini R; Maggioni AP
    Ital Heart J; 2000 Apr; 1(4):282-8. PubMed ID: 10824729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema.
    Karmpaliotis D; Kirtane AJ; Ruisi CP; Polonsky T; Malhotra A; Talmor D; Kosmidou I; Jarolim P; de Lemos JA; Sabatine MS; Gibson CM; Morrow D
    Chest; 2007 Apr; 131(4):964-71. PubMed ID: 17426196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between microvascular dysfunction and B-type natriuretic peptide levels in non-ischemic heart failure patients with cardiac fibrosis.
    Hirakawa K; Yamamuro M; Uemura T; Takashio S; Kaikita K; Utsunomiya D; Nakayama M; Yamamoto E; Yamashita Y; Hokimoto S; Tsujita K
    Int J Cardiol; 2017 Feb; 228():881-885. PubMed ID: 27889555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Values of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in evaluation of cardiac function in children with congenital heart disease].
    Zhang SR; Zhang YH; Xu Q; Qiu HX; Chen Q
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jun; 11(6):429-32. PubMed ID: 19558803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B-type natriuretic peptide: powerful predictor of end-stage chronic heart failure in individuals with systolic dysfunction of the systemic right ventricle.
    Hegarova M; Brotanek J; Kubanek M; Kockova R; Franekova J; Lanska V; Netuka I; Melenovsky V; Malek I; Kautzner J
    Croat Med J; 2016 Aug; 57(4):343-50. PubMed ID: 27586549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.